Taiwan Advance Bio-Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Taiwan Advance Bio-Pharmaceutical has been growing earnings at an average annual rate of 35.1%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 11.5% per year.
Key information
35.1%
Earnings growth rate
40.3%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 11.5% |
| Return on equity | -4.6% |
| Net Margin | -3.4% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Taiwan Advance Bio-Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 316 | -11 | 179 | 17 |
| 30 Sep 23 | 298 | -26 | 176 | 17 |
| 30 Jun 23 | 279 | -41 | 173 | 17 |
| 31 Mar 23 | 299 | -19 | 170 | 16 |
| 31 Dec 22 | 318 | 3 | 169 | 16 |
| 30 Sep 22 | 301 | -35 | 172 | 25 |
| 30 Jun 22 | 285 | -74 | 176 | 34 |
| 31 Mar 22 | 264 | -96 | 179 | 40 |
| 31 Dec 21 | 243 | -119 | 182 | 46 |
| 30 Sep 21 | 243 | -116 | 184 | 44 |
| 30 Jun 21 | 242 | -114 | 187 | 43 |
| 31 Mar 21 | 239 | -100 | 180 | 41 |
| 31 Dec 20 | 236 | -86 | 173 | 39 |
| 30 Sep 20 | 239 | -92 | 182 | 40 |
| 30 Jun 20 | 243 | -98 | 191 | 42 |
| 31 Mar 20 | 224 | -137 | 195 | 54 |
| 31 Dec 19 | 206 | -175 | 199 | 67 |
| 30 Sep 19 | 192 | -188 | 180 | 86 |
| 30 Jun 19 | 178 | -200 | 161 | 106 |
| 31 Mar 19 | 173 | -167 | 149 | 108 |
| 31 Dec 18 | 168 | -133 | 138 | 110 |
| 30 Sep 18 | 163 | -92 | 128 | 91 |
| 30 Jun 18 | 158 | -52 | 118 | 71 |
| 31 Mar 18 | 152 | -75 | 120 | 65 |
| 31 Dec 17 | 145 | -98 | 122 | 59 |
| 30 Sep 17 | 132 | -111 | 121 | 64 |
| 30 Jun 17 | 120 | -123 | 120 | 69 |
| 31 Mar 17 | 120 | -113 | 115 | 75 |
| 31 Dec 16 | 120 | -102 | 110 | 80 |
| 30 Sep 16 | 130 | -105 | 116 | 89 |
| 30 Jun 16 | 140 | -107 | 122 | 97 |
| 31 Mar 16 | 145 | -104 | 124 | 94 |
| 31 Dec 15 | 151 | -100 | 126 | 91 |
| 30 Sep 15 | 145 | -94 | 127 | 83 |
| 30 Jun 15 | 139 | -88 | 127 | 75 |
| 31 Mar 15 | 140 | -94 | 129 | 71 |
| 31 Dec 14 | 141 | -100 | 131 | 67 |
| 30 Sep 14 | 148 | -44 | 130 | 59 |
| 30 Jun 14 | 156 | 12 | 129 | 51 |
| 31 Mar 14 | 160 | 15 | 132 | 45 |
| 31 Dec 13 | 163 | 18 | 135 | 40 |
| 30 Sep 13 | 177 | -1 | 140 | 41 |
| 30 Jun 13 | 191 | -20 | 144 | 43 |
Quality Earnings: 4186 is currently unprofitable.
Growing Profit Margin: 4186 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4186 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.1% per year.
Accelerating Growth: Unable to compare 4186's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4186 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: 4186 has a negative Return on Equity (-4.57%), as it is currently unprofitable.